Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model

Chai, Louis F.; Hardaway, John C.; Heatherton, Kara R.; O’Connell, Kyle P.; LaPorte, Jason; Guha, Prajna; Lopes, Mikayla; Rabinowitz, Benjamin A.; Jaroch, David; Cox, Bryan F.; Knight, Robert D.; Katz, Steven C.

doi:10.1016/j.jss.2021.11.001

Cited by 5 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To improve efficacy against peritoneal metastases, intraperitoneal (IP) delivery of CAR T-cells have been assessed. Compared with systemic intravenous delivery, regional IP infusion of anti-CEA CAR T-cells effectively protects against CEA+ peritoneal tumors and metastasis, enhances the effector memory response and is associated with increased IFNγ production ( 70 ). Therefore, it has been suggested that regional delivery improves CAR T-cell penetration deep inside solid tumors without increasing toxicity or overcoming barriers associated with systemic delivery.…”

Section: Promising Role For Car T-cells In Crcmentioning

confidence: 99%

CAR T-cells for colorectal cancer immunotherapy: Ready to go?

et al. 2022

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cells represent a new genetically engineered cell-based immunotherapy tool against cancer. The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies. Unfortunately, there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer. CAR T-cell therapy for colorectal cancer is still in its early stages, and clinical data are scarce. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment for CAR T-cell therapy in colorectal cancer. In this review, we summarize current knowledge, highlight challenges, and discuss perspectives regarding CAR T-cell therapy in colorectal cancer.

show abstract

Section: Promising Role For Car T-cells In Crcmentioning

confidence: 99%

CAR T-cells for colorectal cancer immunotherapy: Ready to go?

et al. 2022

View full text Add to dashboard Cite

show abstract

“… Higher doses can exert an antitumor effect. - Liver metastases of colorectal cancer were 40 High pressure area delivery 2 The tumor burden was significantly reduced. - Improving the likelihood of durable tumor control and mitigate toxicity Low pressure area delivery 2 The tumor burden was reduced.…”

Section: Introductionmentioning

confidence: 99%

“… 24 , 37 Regional delivery of high pressure and low pressure requires a series of regulation of pressure. 40 Moreover, the way difficulty of intratumoral in situ injection is also greatly increased due to the complexity of the intratumoral vasculature. In contrast, for common primary tumors, regional administration is a more ideal way of administration for both therapeutic effects and adverse effects (NCT03198546).…”

Section: Introductionmentioning

confidence: 99%

CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working

Zhu¹,

Feng²,

Wan³

et al. 2023

DDDT

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cell therapy, as an innovative immunotherapy, plays a huge role in current cancer therapy. Although CAR T cell therapy has demonstrated therapeutic effects in some subtypes of B cell leukemia or lymphoma, there are many challenges that limit the therapeutic efficacy of CAR T cells in solid tumors. And how to efficiently transport CAR T cells to tumor tissues is a continuing concern for us. In this review, experiments have been extensively studied and compared. We finally compared the influence of different injection methods on therapeutic efficacy. We also carefully explored the difficulties of designing, homing, and working of CAR T cells, and ultimately came up with better solutions for each process to help CAR T cells reach tumor tissue more efficiently and quickly. These results will have significant implications for guiding CAR T cell therapy in cancer treatment.

show abstract